This site uses cookies to improve your browsing experience; the website may not work as expected without them. By continuing to browse this site, you consent to the use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy
Santhera and ReveraGen to Present Efficacy and Safety Data with Vamorolone at 2022 Muscular Dystrophy Association Conference
Pratteln, Switzerland, and Rockville, MD, USA, March 15, 2022
Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce presentations of efficacy and tolerability data with vamorolone in Duchenne muscular dystrophy (DMD) at the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific
Santhera and ReveraGen Announce Positive and Statistically Highly Significant Topline Results with Vamorolone in Pivotal VISION-DMD Study
Pratteln, Switzerland, and Rockville, MD, USA, June 1, 2021
Santhera and ReveraGen Announce FDA Acceptance of New Drug Application for Vamorolone in Duchenne Muscular Dystrophy
ReveraGen Receives $3.3 Million NIH Commercialization Readiness Pilot Grant for NDA Preparations for Vamorolone in Duchenne Muscular Dystrophy
Rockville, MD, USA, November 17, 2020
ReveraGen, Inc., a privately held company developing vamorolone (VBP15) as a potential safer alternative for corticosteroid treatment in Duchenne muscular dystrophy and other disorders, today announced an award of a $3.3 million grant
Santhera Announces Publication of Long-Term Clinical Data with Vamorolone in Patients with Duchenne Muscular Dystrophy
Pratteln, Switzerland, and Rockville, MD, USA, September 22, 2020
Santhera Pharmaceuticals (SIX: SANN) announces that partner ReveraGen Biopharma Inc. and their academic collaborators have published new open-label, long-term clinical data
Santhera Announces Publication on Molecular Distinctions of Vamorolone Compared to Corticosteroids
Pratteln, Switzerland, and Rockville, MD, USA, September 14, 2020
Santhera Pharmaceuticals (SIX: SANN) announces that Emory University scientists and partner ReveraGen Biopharma Inc. have published new data on the molecular mode of action of vamorolone compared to standard corticosteroids
Santhera Announces Full Enrollment of ReveraGen’s Pivotal VISION-DMD Study with Vamorolone in Duchenne Muscular Dystrophy
Pratteln, Switzerland, and Rockville, MD, USA, September 11, 2020
Santhera Pharmaceuticals (SIX: SANN) announces that partner ReveraGen Biopharma Inc. has completed enrollment into the pivotal VISION-DMD study with vamorolone in patients with Duchenne muscular dystrophy (DMD).
Santhera Exercises Option to Obtain Worldwide Rights to Vamorolone in Duchenne Muscular Dystrophy and All Other Indications
Pratteln, Switzerland, and Rockville, MD, USA, September 2, 2020
Santhera Pharmaceuticals (SIX: SANN) announces that it has signed agreements with Idorsia (SIX: IDIA) and ReveraGen BioPharma Inc., making Santhera a direct license holder of vamorolone.
Jesse’s Journey grants $1M toward the launch of a clinical trial for Duchenne muscular dystrophy in Canada
Rockville MD, 11 June 2020
Jesse’s Journey, Canada’s leader in Duchenne muscular dystrophy funded research, is proud to announce a $1M grant towards a clinical trial evaluating vamorolone for the first time in
ReveraGen BioPharma completes 2.5 years vamorolone treatment of 41 Duchenne muscular dystrophy boys
Rockville MD, 2 June 2020
Vamorolone is a first-in-class daily oral drug being developed to improve muscle function in Duchenne muscular dystrophy. Vamorolone has multiple mechanisms of action shown by published pre-clinical studies, including potent anti-inflammatory
ReveraGen BioPharma receives National Institutes of Health ethics grant to return data to participants in vamorolone clinical trials
Rockville MD, 22 October 2019
The National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (USA) has awarded an ethics research grant to ReveraGen BioPharma to return patient-level and aggregate data to